InvestorsHub Logo
Followers 43
Posts 2488
Boards Moderated 0
Alias Born 10/19/2015

Re: McMagyar post# 197938

Tuesday, 06/25/2019 1:08:53 PM

Tuesday, June 25, 2019 1:08:53 PM

Post# of 468938
Time is always the factor. Anavex's price hasn't moved much in the past 2 or 3 years. This means that it's found its rightful value for the time being.

Whether the competition stands to gain or lose is irrelevant. Anavex's value doesn't depend on the decisions Biogen or any other company makes. If A273 succeeds, Anavex becomes an acquisition target. If it flops, it'll go to zero.

Big Pharma isn't taking the risk of partnering until they see more evidence that Sigma1 is the answer. Same with hedge funds -- they aren't going to invest until they see more data. Doesn't change anything with regards to AVXL's intrinsic value.

Five years ago someone was willing to pay $15/share, and today only $3. Same stock, more data now than back then. What's changed?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News